Details for New Drug Application (NDA): 012972
✉ Email this page to a colleague
NDA 012972 describes METATENSIN #4, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. Additional details are available on the METATENSIN #4 profile page.
The generic ingredient in METATENSIN #4 is reserpine; trichlormethiazide. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine; trichlormethiazide profile page.
The generic ingredient in METATENSIN #4 is reserpine; trichlormethiazide. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine; trichlormethiazide profile page.
Summary for 012972
| Tradename: | METATENSIN #4 |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | reserpine; trichlormethiazide |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.1MG;2MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.1MG;4MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
